Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2018 | Review

The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII

Authors: Antonietta Rosella Farina, Lucia Cappabianca, Pierdomenico Ruggeri, Luciana Gneo, Cristina Pellegrini, Maria-Concetta Fargnoli, Andrew Reay Mackay

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2018

Abstract

Oncogenes derived from the neurotrophin receptor tropomyosin-related kinase TrkA act as drivers in sub-populations of a wide-range of human cancers. This, combined with a recent report that both adult and childhood cancers driven by novel oncogenic TrkA chimeric-fusions exhibit profound, long-lived therapeutic responses to the Trk inhibitor Larotrectinib, highlights the need to improve clinical detection of TrkA oncogene-driven cancers in order to maximise this novel therapeutic potential. Cancers potentially driven by TrkA oncogenes include a proportion of paediatric neuroblastomas (NBs) that express the alternative TrkA splice variant TrkAIII, which exhibits exon 6, 7 and 9 skipping and oncogenic-activity that depends upon deletion of the extracellular D4 Ig-like domain. In contrast to fully spliced TrkA, which exhibits tumour suppressor activity in NB and associates with good prognosis, TrkAIII associates with advanced stage metastatic disease, post therapeutic relapse and worse prognosis, induces malignant transformation of NIH-3T3 cells and exhibits oncogenic activity in NB models. TrkAIII induction in NB cells is stress-regulated by conditions that mimic hypoxia or perturbate the ER with potential to change TrkA tumour-suppressing signals into oncogenic TrkAIII signals within the stressful tumour microenvironment. In contrast to cell surface TrkA, TrkAIII re-localises to intracellular pre-Golgi membranes, centrosomes and mitochondria, within which it exhibits spontaneous ligand-independent activation, triggering a variety of mechanisms that promote tumorigenicity and malignant behaviour, which impact the majority of cancer hallmarks. In this review, we present updates on TrkAIII detection and association with human malignancies, the multiple ways TrkAIII exerts oncogenic activity and potential therapeutic approaches for TrkAIII expressing cancers, with particular reference to NB.

Ruggeri P, Farina AR, Cappabianca L, Ianni N, Ragone M, Merolla S, et al. Neurotrophin and neurotrophin receptor involvement in human neuroblastoma. In: Neuroblastoma, Prof Hiroyuki Shimada (Ed.). InTech, doi:https://doi.org/10.5772/55536.

Aleo L, Rocco ML, Omar B, Micera A. Nerve growth factor: role in growth, differentiation and controlling cancer development. J Exp Clin Cancer Res. 2016;35:116. https://doi.org/10.1186/s13046-016-0395-y.CrossRef

Martin-Zanca D, Hughes SH, Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature. 1986;319:743–8.CrossRefPubMed

Klein R, Jing S, Namduri V, O’Rourke E, Barbacid M. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell. 1991;65:189–7.CrossRefPubMed

Coulier F, Kumar R, Ernst M, Klein R, Martin-Zanca D, Barnacid M. Human Trk oncogenes activated by point mutation, in-frame deletion, and duplication of the tyrosine kinase domain. Mol Cell Biol. 1990;10:4202–10.CrossRefPubMedPubMedCentral

Greco A, Pierotti MA, Bongarzone I, Pagliardi S, Lanzi C, Della Porta G. Trk-T1 is a novel oncogene formed by the fusion of TPR and Trk genes in human papillary thyroid carcinomas. Oncogene. 1992;7:237–42.PubMed

Greco A, Mariani C, Miranda C, Lupas A, Pagliardini S, Pomati M, et al. The DNA rearrangement that generates the TrkT3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol Cell Biol. 1995;15:6118–27.CrossRefPubMedPubMedCentral

George DJ, Suzuki H, Bova SG, Isaacs JT. Mutational analysis of the TrkA gene in prostate cancer. Prostate. 1998;36:172–80.CrossRefPubMed

Reuther GW, Lambert QT, Caligiuri MA, Der CJ. Identification and characterisation of an activating TrkA deletion mutation in acute myeloid leukemia. Mol Cell Biol. 2000;20:8655–66.CrossRefPubMedPubMedCentral

10.

Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, Yeh I, et al. Kinase fusions are frequent in Spitz tumours and Spizoid melanomas. Nat Commun. 2014;5:3116. https://doi.org/10.1038/ncomms4116.CrossRefPubMed

11.

Sartore-Bianchi A, Ardini E, Bosotti R, Amatu A, Valtorta E, Somaschini A, et al. Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer. J Natl Cancer Inst. 2016;108 https://doi.org/10.1093/jnci/djv306.

12.

Wong V, Pavlick D, Brennan T, Yelensky R, Crawford J, Ross JS, et al. Evaluation of a congenital infantile fibrosarcoma by comprehensive genomic profiling reveals an LMNA-NTRK gene fusion responsive to crizotinib. J Natl Cancer Inst. 2016;108 https://doi.org/10.1093/jnci/djv307.

13.

Lockwood WW, Chari R, Coe BP, Girard L, MacAulay C, lam S, et al. DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. Oncogene. 2008;27:4615–24.CrossRefPubMedPubMedCentral

14.

Lee SJ, Kim NKD, Lee S-H, Kim ST, Park SH, Park JO, et al. NTRK gene amplification in patients with metastatic cancer. Prec Futur Med. 2017;1:129–37.CrossRef

15.

Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1:e000023. https://doi.org/10.1136/esmopen-2015-000023.CrossRefPubMedPubMedCentral

16.

Vaishnavi A, Le AT, Doeble RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Disc. 2015;5:25–34.CrossRef

17.

Lange AM, Lo H-W. Inhibiting TRK proteins in clinical Cancer therapy. Cancers. 2018;10 https://doi.org/10.3390/cancers10040105.

18.

Drilon A, Laetsch TW, Kummer S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of Larotrectinib in Trk-fusion-positive cancer in adults and children. N Engl J Med. 2018;378:731–9.CrossRefPubMedPubMedCentral

19.

Tacconelli A, Farina AR, Cappabianca L, DeSantis G, Tessitore A, Vetuschi A, et al. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell. 2004;6:347–60.CrossRefPubMed

20.

Schramm A, Schowe B, Fielitz K, Heilman M, Martin M, Marshall T, et al. Exon-level expression analysis identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict neuroblastoma outcome. Br J Cancer. 2012;107:1409–17.CrossRefPubMedPubMedCentral

21.

Simpson AM, Iyer R, Mangino JL, Minturn JE, Zhao H, Kolla V, et al. TrkAIII isoform expression upregulates stem cell markers and correlates with worse outcome in neuroblastomas (NBs). Proc Adv Neuroblast Res. 2012;164:POT055.

22.

Luberg K, Park R, Aleksejeva E, Timmusk T. Novel transcripts reveal a complex structure of the human TrkA gene and imply the presence of multiple protein isoforms. MBC Neurosci. 2015;16:78. doi.org/10.1186/s12868-015-0215-x

23.

Farina AR, Cappabianca L, Ruggeri P, Di Ianni N, Ragone M, Merolla S, et al. Alternative TrkA splicing and neuroblastoma. In: Neuroblastoma - Present and Future. London: Prof Hiroyuki Shimada (Ed) ISBN:978–953–307-016-2. InTech. 2012:111–136.

24.

Florenes VA, Maelandsmo GM, Holm R, Reich R, Lazarovici P, Davidson B. Expression of activated TrkA protein in melanocytic tumors. Am J Clin Pathol. 2004;122:412–20.CrossRefPubMed

25.

Pasini L, Re A, Tebaldi T, Ricci G, Boi S, Adami V, et al. TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines. BMC Cancer. 2015;15:777. https://doi.org/10.1186/s12885-015-1791-y.CrossRefPubMedPubMedCentral

26.

Farina AR, Tacconelli A, Cappabianca L, Cea G, Panella S, Chioda A, et al. The alternative TrkAIII splice variant targets the centrosome and promotes genetic instability. Mol Cell Biol. 2009;29:4812–30.CrossRefPubMedPubMedCentral

27.

Tacconelli A, Farina AR, Cappabianca L, Cea G, Panella S, Chioda A, et al. TrkAIII expression in the thymus. J Neuroimmunol. 2007;183:151–61.CrossRefPubMed

28.

Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J. 2013;280:5350–70.CrossRefPubMed

29.

Tacconelli A, Farina AR, Cappabianca L, Gulino A, Mackay AR. Alternative TrkAIII splicing: a potential regulated tumor promoting switch in neuroblastoma. Future Oncol. 2005;1:689–98.CrossRefPubMed

30.

Kavsan VM, Iershov AV, Balynska OV. Immortalized cells and one oncogene in malignant transformation: old insights on new explanation. BMC Cell Biol. 2011;12:23. https://doi.org/10.1186/1471-2121-12-23.CrossRefPubMedPubMedCentral

31.

Arevalo JC, Conde B, Hempstead BL, Chao MV, Martin-Zanca D, Perez P. TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor. Mol Cell Biol. 2000;20:5908–16.CrossRefPubMedPubMedCentral

32.

Farina AR, Cappabianca L, Gneo L, Ruggeri P, Mackay AR. TrkAIII signals endoplasmic reticulum stress to the mitochondria in neuroblastoma cells, resulting in glycolytic metabolic adaptation. Oncotarget. 2018;9:8368–90.CrossRefPubMed

33.

Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Laquaglia MJ, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455:930–5.CrossRefPubMedPubMedCentral

34.

Boutterin MC, Mazot P, Faure C, Doly S, Gervasi N, Tremblay MI, et al. Control of ALK (wild type and mutated forms) phosphorylation: specific role for the phosphatase PTP1B. Cell Signal. 2013;25:1505–13.CrossRefPubMed

35.

Shi W, George SK, George B, Curry CV, Murzabdillaeva A, Alkan S, et al. TrkA is a binding partner of NPM-Alk that promotes survival of ALK+ T-cell lymphoma. Mol Oncol. 2017;11:1189–207.CrossRefPubMedPubMedCentral

36.

Brodeur GM. Spontaneous regression of neuroblastoma. Cell Tissue Res. 2018;372:277–86.CrossRefPubMedPubMedCentral

37.

Bochetta M, Di Resta I, Powers A, Fresco R, Tosolini A, Testa JR, et al. Human mesothelioma cells are unusually susceptible to simian virus 40-mediated transformation and asbestos carcinogenicity. Proc Natl Acad Sci U S A. 2000;97:10214–9.CrossRef

38.

IARC Monographs on the evaluation of carcinogenic risks to humans Malaria and some polyoma viruses (SV40, BK, JC and Merkel cell viruses) (World Health Organisation international agency for research of Cancer, Geneva Switerland) 2014;104:133–251.

39.

Iwakura H, Ariyasu H, Kanamoto N, Hosoda K, Nakao K, Kangawa K, et al. Establishment of a novel neuroblastoma mouse model. Int J Oncol. 2008;33:1195–9.PubMed

40.

Farina AR, Cappabianca L, Ruggeri P, Gneo L, Maccarone R, Mackay AR. Retrograde TrkAIII transport from ERGIC to ER: a re-localisation mechanism for oncogenic activity. Oncotarget. 2015;6:35636–51.CrossRefPubMedPubMedCentral

41.

Chen J, Crutchley J, Zhang D, Owzar K, Kastan MB. Identification of a DNA damage-response alternative splicing pathway that regulates p53 and cellular senescence markers. Cancer Discov. 2017;7:766–81.CrossRefPubMedPubMedCentral

42.

Li Z, Vuong JK, Zhang M, Stork C, Zheng S. Inhibition of nonsense-mediated RNA decay by ER stress. RNA. 2017;23:378–94.CrossRefPubMedPubMedCentral

43.

Goto N. Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins. Cancer Sci. 2008;99:1319–25.CrossRef

44.

Eggert A, Grotzer MA, Ikegaki N, Liu XG, Evans AE, Brodeur GM. Expression of neurotrophin receptor TrkA inhibits angiogenesis in neuroblastoma. Med Pediatr Oncol. 2000;35:569–72.CrossRefPubMed

45.

Eggert A, Grotzer MA, Ikegaki N, Liu XG, Evans AE, Brodeur GM. Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Res. 2002;62:1802–8.PubMed

46.

Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2:737–44.CrossRefPubMedPubMedCentral

47.

Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial cell growth factor. Proc Natl Acad Sci U S A. 2001;98:12485–90.CrossRefPubMedPubMedCentral

48.

Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP-3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nature Med. 2003;9:407–15.CrossRefPubMed

49.

Ruggeri P, Farina AR, Di Ianni N, Cappabianca L, Ragone M, Ianni G, et al. The TrkAIII oncoprotein inhibits mitochondrial free radical ROS-induced death of SH-SY5Y neuroblastoma cells by augmenting SOD-2 expression and activity at the mitochondria, within the context of a tumor stem cell-like phenotype. PLoS One. 2014;15:e94568.CrossRef

50.

Farina AR, Tacconelli A, Cappabianca L, Cea G, Chioda A, Romanelli A, et al. The neuroblastoma tumour suppressor TrkAI and its oncogenic alternative TrkAIII splice variant exhibit geldanamycin-sensitive interactions with Hsp90 in human neuroblastoma cells. Oncogene. 2009;28:4075–94.CrossRefPubMed

51.

Farina AR, Di Ianni N, Cappabianca L, Ruggeri P, Ragone M, Ianni G, et al. TrkAIII promotes microtubule nucleation and assembly at the centrosome in SH-SY5Y neuroblastoma cells, contributing to an undifferentiated anaplastic phenotype. Biomed Res Int. 2013;2013:740187. https://doi.org/10.1155/2013/740187.PubMedPubMedCentralCrossRef

52.

Moughamian AJ, Osborn GE, Lazurus JE, Maday S, Holzbauer ELF. Predered recruitment of dynactin to the microtubule plus end is required for efficient initiation of retrograde axonal transport. J Neurosci. 2013;33:13190–203.CrossRefPubMedPubMedCentral

53.

Watson FL, Porcionatto MA, Battacharyya A, Stiles CD, Segal RA. TrkA glycosylation regulates localisation and activity. J Neurobiol. 1999;39:323–36.CrossRefPubMed

54.

Farina AR, Cappabianca L, Ruggeri P, Gneo L, Mackay AR. The enemy from within: mislocalization of a compromised receptor as a mechanism for TrkAIII oncogenic activity. Cancer Cell Microenviron. 2016;3(1):1–5. https://doi.org/10.14800/com.1205.

55.

Johnson A, Bhattachary N, Hanna M, Pennington JG, Schuh A, Wang L, et al. TGF clusters COPII-coated transport carriers and promotes early secretory pathway organisation. EMBO J. 2015;7:811–27.CrossRef

56.

Schectersen LC, Hudson MP, Ko M, Philippidou P, Akmentin W, Wiley J, et al. Trk activation in the secretory pathway promotes Golgi fragmentation. Mol Cell Neurosci. 2010;43:403–13.CrossRef

57.

Prior IA, Hancock JF. Ras trafficking, localisation and compartmentalised signaling. Semin Cell Dev Biol. 2012;23:145–53.CrossRefPubMed

58.

Gneo L, Ruggeri P, Cappabianca L, Farina AR, Di Ianni N, Mackay AR. TRAIL induces pro-apoptotic crosstalk between the TRAIL-receptor signaling pathway and TrkAIII in SH-SY5Y cells, unveiling a potential therapeutic “Achilles heel” for the TrkAIII oncoprotein in neuroblastoma. Oncotarget. 2016;7:80820–41.CrossRefPubMedPubMedCentral

59.

Li Y, Guo Y, Tang J, Jiang J, Vhen Z. New insights into the roles of CHOP-induced apoptosis in ER stress. Acta Biochim Biophysi Sin. 2014;46:629–40.CrossRef

60.

Corazzari M, Gagliardi M, Fimia GM, Piacentini M. Endoplasmic reticulum stress, unfolded protein response and cancer cell fate. Frontiers in Oncol. 2017;7 https://doi.org/10.3389/fonc.2017.00078.

61.

Hetz C, Lee A-W, Gonzalez-Romero D, Thielen P, Castilla J, Soto C, et al. Unfolded protein response transcription factor XBP-1 does not influence prion replication or pathogenesis. Proc Nat Acad Sci USA. 2008;105:757–62.CrossRefPubMedPubMedCentral

62.

Bakhoum SF, Ngo B, Laughney AM, Cavallo J-A, Murphy CJ, Ly P, et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature. 2018;533:467–72.CrossRef

63.

Sarni D, Kerem B. Oncogene-induced replication stress drives genome instability and tumorigenesis. Int J Mol Sci. 2017;18:1339. https://doi.org/10.3390/ijms18071339.CrossRefPubMedCentral

64.

Ruan L, Zhou C, Jin E, Kucharavy A, Zhang Y, Wen Z, et al. Cytosol proteostasis through importing of misfolded proteins into mitochondria. Nature. 2017;543:443–6.CrossRefPubMedPubMedCentral

65.

Libert MV, Locasale JW. The Warburg effect: how does it benefit cancer cells. Trends in Biochem Sci. 2016;41:211–8.CrossRef

66.

Lee N, Kim D. Cancer metabolism: Fuelling more than just growth. Mol Cells. 2016;39:847–54.CrossRefPubMedPubMedCentral

67.

Menendez JA, Joven J, Cufi S, Corominas-Faja B, Oliveras-Ferraros C, Cuyas E, et al. The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. Cell Cycle. 2013;12:1166–79.CrossRefPubMedPubMedCentral

68.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.CrossRefPubMed

69.

Bailey JJ, Schirrmacher R, Farrell K, Bernard-Gauthier V. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – part II. Exp Op Ther Pat. 2017; https://doi.org/10.1080/13543776.2017.1297797.

70.

Suvarna V, Murahari M, Khan T, Chaubey P, Sangave P. Phytochemicals and PI3K inhibitors in Cancer - an insight. Front Pharmacol. 2017;8 https://doi.org/10.3389/fpharm.2017.00916.

71.

Janku F, Yap TA, Meric-Bernstam F. Targeting PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol. 2018;15:273–91.CrossRefPubMed

72.

Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NF-kB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta. 2010;1799:775–87.CrossRefPubMedPubMedCentral

73.

Booth L, Cazanave SC, Hamed HA, Yacoub A, Ogretmen B, Chen C-S, et al. OSU-30102 suppresses GRP78/BiP expression that causes PERK-dependent increase in tumor cell killing. Cancer Biol Ther. 2012;13:2234–6.

74.

Vogler M. Targeting BCL2-proteins for the treatment of solid tumours. Adv Med. 2014;2014 https://doi.org/10.1155/2014/943648.

75.

Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, et al. Targeting Mcl-1 for the therapy of cancer. Exp Op Invest Drugs. 2011;20:1397–411.CrossRef

76.

Song Y-H, Wang J, Nie G, Chen Y-J, Li X, Jiang X, et al. MicroRNA-509-5p functions as an anti-oncogene in breast cancer via targeting SOD2. Eur Rev Med Pharmacol Sci. 2017;21:3617–25.PubMed

77.

Hempel N, Carrico PM, Melendez JA. Manganese superoxide dismutase (Sod2) redox-control of signaling events that drive metastasis. Anti Cancer Agents Med Chem. 2011;11:191–201.CrossRef

78.

Von Karsdtedt S, Montinaro A, Walczak H. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat Rev Cancer. 2017;17:352–66.CrossRef

79.

Wu X, Wang S, Li M, Wang A, Zhou Y, Li P, et al. Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy. Nano. 2017;9:13879–904.

80.

Dubuisson A, Micheau O. Antibodies and derivatives targeting DR4 and DR5 for cancer therapy. Antibodies. 2017;6:16. https://doi.org/10.3390/antib40016. CrossRefPubMedCentral

81.

Ruggeri P, Cappabianca L, Farina AR, Gneo L, Mackay AR. NGF sensitizes TrkA SH-SY5Y neuroblastoma cells to TRAIL-induced apoptosis. Cell Death Discov. 2016;2:16004. https://doi.org/10.1038/cddiscovery.2016.4.CrossRefPubMedPubMedCentral

82.

Bagatell R, Gore L, Egorin MJ, Ho R, Heller G, Boucher N, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res. 2007;13:1783–8.CrossRefPubMed

Title: The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII
Authors: Antonietta Rosella Farina
Lucia Cappabianca
Pierdomenico Ruggeri
Luciana Gneo
Cristina Pellegrini
Maria-Concetta Fargnoli
Andrew Reay Mackay
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2018
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-018-0786-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Regorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling

IL-33 facilitates proliferation of colorectal cancer dependent on COX2/PGE2

Distinct expression profiles and functions of Kindlins in breast cancer

LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1

Inhibitory effects of low intensity pulsed ultrasound on osteoclastogenesis induced in vitro by breast cancer cells

Dysregulation of miR-6868-5p/FOXM1 circuit contributes to colorectal cancer angiogenesis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer